When white blood cells are removed may affect stored blood quality
NCT ID NCT07821736
First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time
Summary
Researchers at Assiut University are studying how the timing of leukoreduction, the removal of white blood cells from donated blood, affects levels of a marker called H3cit and the quality of stored red blood cells. The study uses 60 standard whole blood units from healthy donors. Scientists measure H3cit at several points during storage and compare it with standard blood storage markers to see whether filtration timing matters.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Timing of leukoreduction (white blood cell removal) during blood processing
- What this could lead to
- If the timing of leukoreduction affects H3cit levels, blood banks could adjust their processing schedules to reduce storage lesions and improve the quality of stored red blood cells for transfusion.
- What could go wrong
- This is a small laboratory study of 60 blood units, not a clinical trial in patients. It may find no meaningful link between leukoreduction timing and H3cit, and any finding would need confirmation in larger studies before changing blood bank practices.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * • Standard whole blood units collected from healthy voluntary donors who meet the national blood transfusion service fitness criteria (age 18-60 years, body weight ≥50 kg). * Collection Volume \& Container: Standard unit volume (450 ± 45 mL) collected into closed bag systems with additive/anticoagulant solution (CPDA-1). * Thermal Storage Chain: Blood units maintained continuously within standard blood bank temperature limits (2 C to 6C )from collection until the end of the storage period. Baseline Hematological Parameters: Normal baseline hematological profile immediately post-collection (Hemoglobin ≥12.5g dl) Exclusion Criteria: * Donor Clinical Factors: Donors with a history of acute or chronic inflammatory conditions, active infections, autoimmune diseases, or those who ingested anti-inflammatory/antiplatelet medications (e.g., NSAIDs, aspirin) within 14 days prior to donation. * Technical Collection Complications: Phlebotomy draw time exceeding 12 minutes, difficult venipuncture, or units displaying macro-clots or excessive lipemia post-collection. * Storage Excursions \& Bag Damage: Any blood unit subjected to cold-chain temperature violations outside 2-6C, physical damage, or system breaches/leaks. Transfusion-Transmitted Infections (TTI): Units testing reactive for screening markers, including HBsAg, Anti-HCV, Anti-HIV-1/2, or Syphilis * Donor Clinical Factors: Donors with a history of acute or chronic inflammatory conditions, active infections, autoimmune diseases, or those who ingested anti-inflammatory/antiplatelet medications (e.g., NSAIDs, aspirin) within 14 days prior to donation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy donors are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Mayar Medhat
Asyut, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.